Proposed Data Collections Submitted for Public Comment and Recommendations, 6571-6572 [E7-2310]
Download as PDF
Federal Register / Vol. 72, No. 28 / Monday, February 12, 2007 / Notices
their blood. However, the microcystin
concentrations in Lake 2 were below the
LOD and in Lake 1 were actually 2ug/
L to 5ug/L, much lower than we
anticipated based on data from the
previous week. Thus, the recreational
exposures were not likely high enough
for us to quantify microcystins in blood
and the serum samples were all below
the LOD for microcystins.
For the new data collection, we will
recruit 100 study participants who are at
risk for swallowing water or inhaling
spray (i.e., water skiers, jet skiers,
people sailing small boats) and who
6571
complete a telephone symptom survey
8–10 days after doing study activities.
The purpose of the new data
collection is to continue assessing the
public health impact of exposure to the
cyanobacterial toxins, microcystins,
during recreational activities. We will
examine the extent of human exposure
to microcystins present in recreational
waters and associated aerosols and
whether serum levels of microcystins
can be used as a biomarker of exposure.
There is no cost to the respondents
other than their time.
would normally be doing these
activities, even in the presence of a
bloom. We may recruit people who train
for organized swimming events (e.g.,
triathlons) in lakes. In addition, we will
recruit 50 study participants from lakes
with no blooms as a comparison group
to assess the health effects associated
with recreational activities on ‘‘clean’’
lakes. Study participants will be asked
to sign a consent form, complete a
symptom survey before and after doing
their recreational water activities,
provide one 10-ml whole blood sample
after their recreational activities, and
ESTIMATE OF ANNUALIZED BURDEN HOURS
Forms
Number of
respondents
Number of responses
per respondent
Average
burden per response (in
hours)
Screening Questionnaire .................................................................................
Pre-exposure Questionnaire ............................................................................
Post-exposure Questionnaire ..........................................................................
10-day post exposure Questionnaire ..............................................................
Total ..........................................................................................................
188
150
150
150
........................
1
1
1
1
........................
10/60
10/60
10/60
10/60
........................
Dated: February 6, 2007.
Joan F. Karr,
Acting Reports Clearance Officer. Centers for
Disease Control and Prevention.
[FR Doc. E7–2309 Filed 2–9–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-07–0630]
sroberts on PROD1PC70 with NOTICES
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Joan Karr, CDC
Acting Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
VerDate Aug<31>2005
19:52 Feb 09, 2007
Jkt 211001
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Work Organization Predictors of
Depression in Women—Extension—The
National Institute for Occupational
Safety and Health (NIOSH), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Depression is a costly and debilitating
occupational health problem. Research
has indicated that the costs to an
organization of treatment for depression
can rival those for heart disease, and
both major depressive disorder and
forms of minor depression have been
found to be associated with more
disability days than other types of
health diagnoses. This may be of
particular relevance for working
women. Various national and
international studies indicate that
women in developed countries
experience depression at up to twice the
rate of men. Studies that have examined
this gender difference have focused on
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Total burden
hours
31
25
25
25
106
social, personality, and genetic
explanations while few have explored
factors in the workplace that may
contribute to the gender differential.
Examples of workplace factors that may
contribute to depression among women
include: Additive workplace and home
responsibilities, lack of control and
authority, and low paying and low
status jobs. Additionally, women are
much more likely to face various types
of discrimination in the workplace than
men, ranging from harassment to
inequalities in hiring and promotional
opportunities, and these types of
stressors have been strongly linked with
psychological distress and other
negative health outcomes. On the
positive side, organizations that are
judged by their employees to value
diversity and employee development
engender lower levels of employee
stress, and those that enforce policies
against discrimination have more
committed employees. Such
organizational practices and policies
may be beneficial for employee mental
health, particularly the mental health of
women.
This research focuses on the following
questions: (1) Which work organization
factors are most predictive of depression
in women, and (2) are there measurable
work organization factors that confer
protection against depression in women
employees?
The research uses repeated measures,
prospective design with data collection
at three points (baseline and 1-year and
2-year follow-ups). A 45-minute survey
E:\FR\FM\12FEN1.SGM
12FEN1
6572
Federal Register / Vol. 72, No. 28 / Monday, February 12, 2007 / Notices
is being administered by telephone to
400 women and men at 16 different
organizations. The survey contains
questions about traditional job stressors
(e.g., changes in workload, social
support, and work roles), stressors not
traditionally examined, but which may
be linked with depressive symptoms
among women (e.g., roles and
responsibilities outside of the
organizational practices/policies of
interest have on depression. Findings
from this prospective study will also
help target future intervention efforts to
reduce occupationally related
depression in women workers. An
extension request is being sought for an
additional three years, in order to finish
data collection. There will be no cost to
the respondents other than their time.
workplace, discrimination, and career
issues) depression symptoms, and
company policies, programs and
practices. One Human Resource (HR)
representative at each company has also
been surveyed about company policies,
programs and practices. Analyses will
determine which work organization
factors are linked with depressive
symptoms and what effect the
ESTIMATED ANNUALIZED BURDEN HOURS
No. of
respondents
Respondents
Employees .......................................................................................................
HR Representatives .........................................................................................
No. of
responses per
respondent
400
16
3
1
Average
burden per
response
(in hours)
45/60
20/60
Total burden
(in hours)
900
5
905
Dated: February 5, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–2310 Filed 2–9–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007D–0027]
Voluntary Self Inspection of Medicated
Feed Manufacturing Facilities; Draft
Compliance Policy Guide; Availability
AGENCY:
Food and Drug Administration,
HHS.
sroberts on PROD1PC70 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft compliance policy
guide (CPG) entitled ‘‘Voluntary Self
Inspection of Medicated Feed
Manufacturing Facilities.’’ This draft
CPG is intended to provide guidance to
the FDA field offices in prioritizing
inspections of medicated feed
manufacturing facilities for compliance
with Current Good Manufacturing
Practices for Medicated Feeds
regulations (CGMP).
DATES: Submit written or electronic
comments on this draft CPG by April 30,
2007 to ensure their adequate
consideration in preparation of the final
document. Submit written comments on
the information collection requirements
by April 13, 2007. General comments on
agency guidance documents are
welcome at any time.
ADDRESSES: Submit written requests for
single copies of this CPG to the Director,
VerDate Aug<31>2005
19:52 Feb 09, 2007
Jkt 211001
Division of Compliance Policy (HFC–
230), Office of Enforcement, Food and
Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857. Send two
self-addressed adhesive labels to assist
that office in processing your request, or
fax your request to 301–827–0482.
Submit written comments on this draft
CPG to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments.
Comments should be identified with the
full title of the CPG and the docket
number found in brackets in the
heading of this document. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the document.
Submit written comments on the
guidance to the Division of Dockets
Management (address above).
Comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: For
Technical Questions Concerning This
CPG: Paul Bachman, Center for
Veterinary Medicine (HFV–230), Food
and Drug Administration, 7519 Standish
Pl., Rockville, MD 20855, 240–276–
9225, e-mail:
Paul.Bachman@fda.hhs.gov.
distribution of medicated animal feed.
The CPG describes a voluntary self
inspection program whereby firms
would conduct their own inspection on
an annual basis and provide the results
of the inspection to us. The proposed
CPG states that in determining its
inspectional priorities for CGMP
inspections for medicated feed
manufacturing establishments, FDA
intends to consider, among other
factors, whether the firm conducts this
voluntary self inspection. We are calling
this approach ‘‘Voluntary Self
Inspection,’’ but the idea has also been
referred to as ‘‘first-party inspection.’’
In addition to seeking comments on
this concept, we are considering
piloting this new approach for at least
1 year once comments have been
received and evaluated. A pilot would
be announced in a separate Federal
Register document.
I. Background
II. Significance of Guidance
This level 1 draft guidance is being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). This draft guidance, when
finalized, will represent the agency’s
current thinking on the topic. It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
method may be used as long as it
satisfies the requirements of applicable
statutes and regulations.
In this CPG, we are announcing a new
proposed approach to assist in
prioritizing inspections to determine an
individual facility’s compliance with
the Federal Food, Drug, and Cosmetics
Act (the act) and CGMP regulations
published in part 225 (21 CFR part 225)
relative to the manufacture and
III. Paperwork Reduction Act of 1995
Under the Paperwork Reduction Act
of 1995 (the PRA) (44 U.S.C. 3501–
3520), Federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\12FEN1.SGM
12FEN1
Agencies
[Federal Register Volume 72, Number 28 (Monday, February 12, 2007)]
[Notices]
[Pages 6571-6572]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-2310]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-07-0630]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960
and send comments to Joan Karr, CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Work Organization Predictors of Depression in Women--Extension--The
National Institute for Occupational Safety and Health (NIOSH), Centers
for Disease Control and Prevention (CDC).
Background and Brief Description
Depression is a costly and debilitating occupational health
problem. Research has indicated that the costs to an organization of
treatment for depression can rival those for heart disease, and both
major depressive disorder and forms of minor depression have been found
to be associated with more disability days than other types of health
diagnoses. This may be of particular relevance for working women.
Various national and international studies indicate that women in
developed countries experience depression at up to twice the rate of
men. Studies that have examined this gender difference have focused on
social, personality, and genetic explanations while few have explored
factors in the workplace that may contribute to the gender
differential. Examples of workplace factors that may contribute to
depression among women include: Additive workplace and home
responsibilities, lack of control and authority, and low paying and low
status jobs. Additionally, women are much more likely to face various
types of discrimination in the workplace than men, ranging from
harassment to inequalities in hiring and promotional opportunities, and
these types of stressors have been strongly linked with psychological
distress and other negative health outcomes. On the positive side,
organizations that are judged by their employees to value diversity and
employee development engender lower levels of employee stress, and
those that enforce policies against discrimination have more committed
employees. Such organizational practices and policies may be beneficial
for employee mental health, particularly the mental health of women.
This research focuses on the following questions: (1) Which work
organization factors are most predictive of depression in women, and
(2) are there measurable work organization factors that confer
protection against depression in women employees?
The research uses repeated measures, prospective design with data
collection at three points (baseline and 1-year and 2-year follow-ups).
A 45-minute survey
[[Page 6572]]
is being administered by telephone to 400 women and men at 16 different
organizations. The survey contains questions about traditional job
stressors (e.g., changes in workload, social support, and work roles),
stressors not traditionally examined, but which may be linked with
depressive symptoms among women (e.g., roles and responsibilities
outside of the workplace, discrimination, and career issues) depression
symptoms, and company policies, programs and practices. One Human
Resource (HR) representative at each company has also been surveyed
about company policies, programs and practices. Analyses will determine
which work organization factors are linked with depressive symptoms and
what effect the organizational practices/policies of interest have on
depression. Findings from this prospective study will also help target
future intervention efforts to reduce occupationally related depression
in women workers. An extension request is being sought for an
additional three years, in order to finish data collection. There will
be no cost to the respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
No. of No. of burden per Total burden
Respondents respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Employees....................................... 400 3 45/60 900
HR Representatives.............................. 16 1 20/60 5
---------------
.............. .............. .............. 905
----------------------------------------------------------------------------------------------------------------
Dated: February 5, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E7-2310 Filed 2-9-07; 8:45 am]
BILLING CODE 4163-18-P